Literature DB >> 10998193

The cannabinoid system and cytokine network.

T W Klein1, B Lane, C A Newton, H Friedman.   

Abstract

Many advances have been made in the last few years concerning our understanding of the receptors and ligands composing the cannabinoid system. Likewise, the science surrounding cytokine biology has advanced enabling us to measure these proteins more precisely as well as understand and interpret the meaning of changes in their levels. Scientists wishing to study the health consequences of smoking marijuana as well as understand the possible role of endogenous cannabimimetic ligands in immune regulation have continued to study the influence of these substances on the regulation and development of the cytokine network. Research has shown that two major cannabinoid receptor subtypes exist and that subtype 1 (CB1) is expressed primarily in the brain whereas subtype 2 (CB2) is expressed primarily in the periphery. A variety of ligands for these receptors based on the cannabinoid structure have been synthesized and studied as well as low affinity compounds, noncannabinoid ligands, and endogenous ligands derived from fatty acid eicosanoids. Highly selective receptor antagonists have also been introduced and studied. Synthetic, low affinity ligands such as (+)-HU-211 and DMH-11C have been shown to cause anti-inflammatory effects possibly through inhibiting the production and action of TNF-alpha and other acute phase cytokines. In addition, suppression of TNF and other cytokines such as GM-CSF, IL-6, IFNgamma, and IL-12 has also been seen following exposure to high affinity and psychoactive ligands such as marijuana and THC. However, some of these ligands have also been shown to increase rather than decrease interleukins such as IL-1, IL-4, IL-10, and IL-6, cytokines such as TNF-alpha, and chemokines such as IL-8, MIP-1, and RANTES. The endogenous ligand, anandamide, has been shown in culture to either suppress the proliferation response to prolactin or enhance the response to cytokines such as IL-3 and IL-6. This eicosanoid has also been shown to increase the production of interleukins and other cytokines. Cannabinoid receptors have been shown to be involved in some but not all of these effects. It is clear that psychoactive and nonpsychoactive compounds have demonstrated effects in vivo and in vitro on the production and function of a variety of cytokines. Depending upon the model system, these effects are often conflicting, and the involvement of cannabinoid receptors is unclear. However, enough evidence exists to suggest that the cannabinoid system significantly impacts the functioning of the cytokine network, and this association may provide clues to the mechanisms of certain immune diseases and form the basis for new immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998193     DOI: 10.1177/153537020022500101

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  61 in total

1.  Dietary fat intake and the brain: a developing frontier in biological psychiatry.

Authors:  C E Greenwood; S N Young
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

Review 2.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

Review 3.  Cannabinoid neuroimmune modulation of SIV disease.

Authors:  Patricia E Molina; Angela Amedee; Nicole J LeCapitaine; Jovanny Zabaleta; Mahesh Mohan; Peter Winsauer; Curtis Vande Stouwe
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-10       Impact factor: 4.147

4.  Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis.

Authors:  Amélie Servettaz; Niloufar Kavian; Carole Nicco; Vanessa Deveaux; Christiane Chéreau; Andrew Wang; Andreas Zimmer; Sophie Lotersztajn; Bernard Weill; Frédéric Batteux
Journal:  Am J Pathol       Date:  2010-05-27       Impact factor: 4.307

Review 5.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 6.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

Review 7.  [The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders].

Authors:  U Schneider; J Seifert; M Karst; J Schlimme; K Cimander; K R Müller-Vahl
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

8.  Effects of AM281, a cannabinoid antagonist, on circulatory deterioration and cytokine production in an endotoxin shock model: comparison with norepinephrine.

Authors:  Yuji Kadoi; Fumio Goto
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

9.  Associations of first trimester co-use of tobacco and Cannabis with prenatal immune response and psychosocial well-being.

Authors:  Kristin Ashford; Amanda Fallin-Bennett; Andrea McCubbin; Amanda Wiggins; Sheila Barnhart; Josh Lile
Journal:  Neurotoxicol Teratol       Date:  2019-03-29       Impact factor: 3.763

10.  Characterization of endocannabinoid-mediated induction of myeloid-derived suppressor cells involving mast cells and MCP-1.

Authors:  Austin R Jackson; Venkatesh L Hegde; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Leukoc Biol       Date:  2013-12-06       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.